Literature DB >> 8261674

Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients.

C Ronco1.   

Abstract

Continuous renal replacement therapies are extensively utilized for the treatment of acute renal failure in the critically ill patient. The arterio-venous circulation has been partially substituted by the veno-venous pump driven circulation. Diffusion has been added to convection in order to increase the small solutes clearance even though sometimes the pure convection is still advantageously utilized. Hemofilters have been changed in hemodiafilters with the possibility of countercurrent dialysate circulation. The blood path geometry has been specifically designed to operate under conditions of low pressure and flow. Therefore lower amounts of heparin are required to maintain the extracorporeal anticoagulation with a reduced risk of bleeding. New techniques and new materials permit us today to carry out continuous therapies with a low rate of complications and an increased percentage of survival among the treated patients. The improved understanding of the multiple organ failure syndrome and the pathophysiology of the septic syndrome, suggest today newer indications for continuous renal replacement therapies. The proposed mechanisms of action of the therapy should be the removal of chemical mediators such as platelet activating factor, interleukin-1 and tumor necrosing factor alfa, not only by a filtration process, but also by the adsorption on the surface and structure of the artificial membrane. These new mechanisms may in part be responsible for the beneficial effects of continuous therapies in the patients affected by acute renal failure and other organ dysfunctions.

Entities:  

Mesh:

Year:  1993        PMID: 8261674

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

1.  Continuous venovenous haemodiafiltration in the acute phase of neonatal maple syrup urine disease.

Authors:  P Jouvet; F Poggi; D Rabier; J L Michel; P Hubert; M Sposito; J M Saudubray; N K Man
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

Review 2.  Acute kidney injury.

Authors:  John A Kellum; Mark L Unruh; Raghavan Murugan
Journal:  BMJ Clin Evid       Date:  2011-03-28

Review 3.  Continuous renal replacement therapies: a brief primer for the neurointensivist.

Authors:  Pritesh Patel; Veena Nandwani; Paul J McCarthy; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

Review 4.  Acute renal failure.

Authors:  John A Kellum; Martine Leblanc; Ramesh Venkataraman
Journal:  BMJ Clin Evid       Date:  2008-09-03

5.  Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis.

Authors:  M Kihara; Y Ikeda; N Takagi; H Fujita; K Shibata; S Masumori; K Shiratori; S Umemura; H Shionoiri; M Ishii
Journal:  Intensive Care Med       Date:  1995-04       Impact factor: 17.440

6.  Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.

Authors:  Ji-Young Choi; Yun-Jeong Kang; Hye Min Jang; Hee-Yeon Jung; Jang-Hee Cho; Sun-Hee Park; Yong-Lim Kim; Chan-Duck Kim
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

7.  Factors Associated with Early Mortality in Critically Ill Patients Following the Initiation of Continuous Renal Replacement Therapy.

Authors:  Youn Kyung Kee; Dahye Kim; Seung-Jung Kim; Duk-Hee Kang; Kyu Bok Choi; Hyung Jung Oh; Dong-Ryeol Ryu
Journal:  J Clin Med       Date:  2018-10-08       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.